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Abstract
In classical Hodgkin lymphoma (cHL) chemotherapeutic regimens are associated with stagnant
rates of secondary malignancies requiring the development of new therapeutic strategies. We and
others have shown that permanently activated Signal Transducer and Activator of Transcription
(STAT) molecules are essential for cHL cells. Recently an overexpression of heat-shock protein 90
(HSP90) in cHL cells has been shown and inhibition of HSP90 seems to affect cHL cell survival. Here
we analysed the effects of HSP90 inhibition by geldanamycin derivative 17-AAG or RNA
interference (RNAi) on aberrant Jak-STAT signaling in cHL cells. Treatment of cHL cell lines with
17-AAG led to reduced cell proliferation and a complete inhibition of STAT1, -3, -5 and -6 tyrosine
phosphorylation probably as a result of reduced protein expression of Janus kinases (Jaks). RNAi-
mediated inhibition of HSP90 showed similar effects on Jak-STAT signaling in L428 cHL cells. These
results suggest a central role of HSP90 in permanently activated Jak-STAT signaling in cHL cells.
Therapeutics targeting HSP90 may be a promising strategy in cHL and other cancer entities
associated with deregulated Jak-STAT pathway activation.
Findings
Classical Hodgkin lymphoma (cHL) is one of the most
frequent lymphoid tumours predominantly derived from
germinal centre B cells. Despite high survival rates, obser-
vations of long-term survivors reveal a high incidence of
chemotherapy-related secondary malignancies as well as a
stagnant rate of relapses and non-responders. Permanent
activation of Signal Transducer and Activator of Transcrip-
tion (STAT) molecules is essential in a number of malig-
nancies regulating cell proliferation, apoptosis, immune
escape and tumor angiogenesis. Especially STAT3 and
STAT6 but probably also STAT5 seem to be associated
with cell proliferation in cHL cell lines of B and T cell ori-
gin [1,2]. The main activators of STAT molecules are
cytokine receptor associated Janus kinases (Jaks). Cochet
and co-workers could show a permanent activation of
Jak1, 2 or 3 in two T cell derived cHL cell lines involved in
cHL cell survival [3]. As shown in Figure 1, a comparable
activation of Jaks could be observed in B-cell derived cHL
cell lines. Especially Jak2 and Tyk2 are found in a phos-
phorylated state in L428, L591 and L1236 cells. Incuba-
tion with tyrphostin AG17, which is capable in inhibition
of STAT phosphorylation in cHL cells [2], is associated
with a loss of phosphorylation in Jak1, Jak2 and Jak3 as
well as a reduction of phosphorylation in Tyk2 within 6 h.
However, it is possible that reduction of Jak phosphoryla-
tion is also partially due to a reduction of Jak protein lev-
els upon AG17 treatment but the reduction of
phosphorylation is much stronger compared to reduction
of Jak protein levels.
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Recently, HSP90-inhibitors geldanamycin and its deriva-
tive 17-AAG have been shown to have anti-proliferative
effects, sensitize for apoptotic stimuli and synergize with
chemotherapy regimens in cHL cell lines [4,5]. It was sug-
gested that HSP90 inhibitors could be used for treatment
of relapsed lymphoma patients in order to substantially
reduce the toxic burden of standard therapies. HSP90 is a
chaperone essential for maturation and stabilization of
multiple client proteins. Thereby it is associated with cru-
cial cellular functions like cell proliferation and survival
by chaperoning key proteins of respective signaling path-
ways. The frequently observed overexpression of HSP90
in certain neoplasias probably leads to a stabilisation of
proto-oncogenes or sustained aberrant signaling in the
malignant cells. Jak1 and Jak2 have been described to
interact with HSP90 and could therefore be involved in a
permanent Jak-STAT signaling in cHL [6]. Due to the over-
expression of HSP90 [4] and the permanent activation of
Jak-STAT signaling [1-3,7,8], we asked the question if
HSP90 supports permanent Jak-STAT signaling in cHL
cells. Inhibition of HSP90 could be associated with the
interruption of permanent STAT activation supporting the
idea to use HSP90 inhibitors in multi-targeting tumor
therapies. Therefore, we analysed the effects of the HSP90-
inhibitor 17-AAG as well as RNA-interference mediated
inhibition of HSP90 on the tyrosine phosphorylation of
STAT1, STAT3, STAT5, STAT6 and protein expression of
Jak1, Jak2, Jak3 and Tyk2 in cHL cells.
First cHL cell lines L428, L1236 and HDLM2 were incu-
bated with 5 μM 17-AAG or DMSO. Cell proliferation was
measured by 3H-Thymidin incorporation and cells were
harvested after 24 h of 17-AAG treatment. Whole cell
extracts were prepared and analysed by immunoblot. As
shown in Figure 2A, incubation of cHL cell lines L428,
L1236 and HDLM2 with 17-AAG is accompanied by an
entire loss of STAT3 and STAT6 tyrosine phosphorylation
in all three cHL cell lines compared to DMSO treated cells.
STAT1 tyrosine phosphorylation (only detectable in
HDLM2 cells) and STAT5 tyrosine phosphorylation were
also abrogated after 24 h of 17-AAG treatment (Figure
2B). Expression of STAT seems to be unaffected by 17-
AAG treatment as shown by unaltered protein amounts
(Figure 2A &2B). Due to the potential chaperone func-
tions of HSP90, we therefore examined the effects of 17-
AAG on protein amount of Jak1, Jak2, Jak3 and Tyk2 in
cHL cells compared to DMSO treated cells (Figure 2C).
Within 24 h of 17-AAG treatment the amount of detecta-
ble Jak1, Jak3 and Tyk2 protein was reduced in all three
analysed cHL cell lines. Expression of Jak2 was slightly
enhanced in cHL cell line L428 and L1236 not affecting
inhibition of permanent tyrosine phosphorylated STATs,
but abrogated in HDLM2 cells. In Figure 2D the strong
inhibition of cell proliferation is shown, which is in line
with the literature [4,5].
In parallel both isoforms of HSP90 (HSP90a and
HSP90b) were targeted by RNA-interference. Due to the
strong expression levels of HSP90 in L428 cells siRNA
transfection was performed twice by nucleofection. The
transient knock-down of HSP90 in L428 cells confirmed
the results obtained with 17-AAG treatment of cHL cells.
HSP90 knock-down also showed a reduction of STAT3, -5
and -6 tyrosine phosphorylation without affecting protein
levels of STATs (Figure 3A). STAT1 phosphorylation was
not congruently detectable in L428 cells. Further analysis
of Jaks in L428 cells also revealed a reduced expression of
Jak1, Jak2, Jak3 and Tyk2 upon HSP90 knock-down (Fig-
ure 3B). In comparison to the results of 17-AAG treated
cells, the knock-down of HSP90 seems to affect all 4 Jaks
whereas 17-AAG had divergent effects on Jak2. As shown
in Figure 3C a reduction of cell proliferation of L428 cells
was visible after knock-down of HSP90. This effect was
Tyrphostine AG17 leads to dephosphorylation of Janus  kinases after 6 h of treatment in cHL cell lines Figure 1
Tyrphostine AG17 leads to dephosphorylation of 
Janus kinases after 6 h of treatment in cHL cell lines. 
Cell lines L428, L591 and L1236 were incubated with DMSO 
or 10 μM AG17 for 6 h as described recently [2]. Tyrosine 
phosphorylation of Jaks was analysed by immunoprecipitation 
(Protein A Microbeads, Miltenyi Biotech) with Jak specific 
antibodys (Jak1 (HR-785), Jak2 (C-20), Jak3 (C-21) and Tyk2 
(C-20) Santa-Cruz) and immunostaining of tyrosine phospho-
rylation by 4G10 antibody (Upstate). Loading controls were 
accomplished by specific antibodys against Jak proteins.Cell Communication and Signaling 2009, 7:17 http://www.biosignaling.com/content/7/1/17
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not as strong as observed in response to 17-AAG, which
could be explained by remaining HSP90 protein expres-
sion due to an incomplete knock-down or due to addi-
tional effects of 17-AAG on HSP90-independent
pathways.
HSP90 has been associated with the stabilization of
mutant forms of oncogenes including the Jak2 mutation
V617F in hematologic diseases [9]. Due to the observed
permanent tyrosine phosphorylation of Jak2 and Tyk2 in
cHL cell lines we analysed cHL cell lines for the presence
of activating mutations. Jak2 V617F and Tyk2 V678F as
well as Jak2 gene variations at D620E and E627E were
sequenced within the cDNA of cHL cells as described pre-
viously [10-12]. In cHL cells lines L428, L1236, L591,
KMH2, HDLM2 and L540 Jak2 is transcribed from the
allele characterised by V617, D620 and E627, therefore no
V617F activating mutations or other changes could be
observed in the transcripts. The absence of Jak2 activating
mutation V617F has recently been published [13]. The
homologous mutation of Jak V617F in Tyk2 named
V678F has been found to activate Tyk2 in the same man-
ner as Jak2 V617F [11]. In all analysed cHL cell lines
(L428, L591, L1236 and HDLM2) no Tyk2 V678F muta-
tion was detected. Moreover, no other mutations within
the sequenced cDNA regions were detected, suggesting no
17-AAG inhibits phosphorylation of STAT1, STAT3, STAT5 and STAT6 (A + B), reduces expression of Jak1, Jak3 and Tyk2 (C)  and cHL cell proliferation (D) Figure 2
17-AAG inhibits phosphorylation of STAT1, STAT3, STAT5 and STAT6 (A + B), reduces expression of Jak1, 
Jak3 and Tyk2 (C) and cHL cell proliferation (D). cHL cell lines L428, L1236 and HDLM2 were treated with DMSO 
(Sigma-Aldrich) or 5 μM 17-AAG (17-(Allylamino)-17-demethoxygeldanamycin, Merck/Calbiochem) for 24 h. STAT tyrosine 
phosphorylation and Jak expression was analysed by immunoblot as described recently [2]. (A + B) Phosphorylation of STAT3 
(Tyr705) (#9131, Cell Signaling Technology), STAT6 (Tyr641) (#9366, Cell Signaling Technology) (A), STAT1 (Tyr701) (#9172, 
Cell Signaling Technology) and STAT5 (Tyr694) (#9351, Cell Signaling Technology) (B) is completely abrogated within 24 h. 
STAT1 tyrosine phosphorylation was only detectable in HDLM2 cells. Protein levels of the STAT molcules remain mostly unal-
tered (Antibodies: STAT1 (#9171) STAT3 (#9132) (Cell Signaling Technology); STAT5 (610191), STAT6 (610291) (BD Trans-
duction Laboratories)) (C) 17-AAG leads to strong reduction of Jak1, Jak3 and Tyk2 expression in L428, L1236 and HDLM2 
cells. Jak2 is enhanced in L428 and L1236 cells and reduced in HDLM2 cells. (D) Incubation of cHL cells with 17-AAG leads 
strong inhibition of cHL cell proliferation. cHL cell proliferation was measured by 3H-Thymidin incorporation after 24 h of 17-
AAG treatment. 3H-Thymidin was added 16 h – 18 h before harvesting. The data is depicted as percentages (DMSO = 100%) 
and error bars mark the standard deviation of three replications.Cell Communication and Signaling 2009, 7:17 http://www.biosignaling.com/content/7/1/17
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stabilization of mutant forms of Jak2 and Tyk2 by HSP90.
This observation is in line with recent reports of autocrine
activation of Jak-STAT signaling in cHL cells [1,14].
In summary, this study shows that HSP90 is important for
the permanent activation of STAT molecules in cHL cells.
Moreover, we conclude that the reduced protein levels of
the Jaks upon inhibition of HSP90 are a major reason for
the decreased STAT phosphorylation after inhibition of
HSP90 by 17-AAG or RNAi against HSP90. Therefore, not
only Jak1 or Jak2 as proposed by Shang and colleagues
but also Jak3 and Tyk2 might be stabilised by HSP90 [6].
As proposed by Cochet and co-workers the activation of
Jaks correlates with STAT activation in cHL cells [3]. This
is in line with our finding that reduced protein amounts
of Jaks lead to a reduced tyrosine phosphorylation of
STATs in cHL cells. Nevertheless, we can not rule out that
other HSP90 client proteins affect the phosphorylation of
the STAT molecules or the expression of the Janus kinases,
but HSP90 inhibition is accompanied by a strong reduc-
tion of permanent Jak-STAT signaling shown to be essen-
tial for cHL cell proliferation. Therefore, it is likely that the
reduced cell proliferation upon HSP90 inhibition is
mainly mediated by abrogation of permanent STAT acti-
vation.
Constitutive activation of NF-κB is another hallmark of
cHL and could promote the expression of IL-13 and there-
fore activation of STATs [15]. The aberrant HSP90 expres-
sion in cHL cells could also be mediated by NF-κB and
represent an additional mechanism to support permanent
activation of STATs [16]. Thereby NF-kB could contribute
to the malignant phenotype of cHL cells due to the stabi-
lization of key proteins of multiple signaling pathways by
HSP90 upregulation. Georgakis and co-workers showed
an inhibition of PI3K/Akt and MEK pathways by 17-AAG
in cHL cells which have been shown to contribute to sur-
vival of cHL cells to some extend [4]. The data presented
here in conjunction with the recent publications outlines
HSP90 as a potent therapeutical target in cHL patients of
advanced stages or relapse. The abrogation of STAT phos-
phorylation of by HSP90 inhibition may be also useful for
other cancer entities with permanently activated STAT
molecules. Orally administered HSP90 inhibitors may
open new perspectives in the treatment of these lym-
phoma by targeting multiple pathways and therefore
eliminating the danger of resistance development
observed in single targeted therapies as with imatinib
mesylat.
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Knock-down of HSP90 leads to reduced phosphorylation of  STATs, downregulation of Jaks and reduced proliferation in  L428 cells Figure 3
Knock-down of HSP90 leads to reduced phosphoryla-
tion of STATs, downregulation of Jaks and reduced 
proliferation in L428 cells. cHL cell line L428 was trans-
fected with 3 μg siRNA against HSP90a& HSP90b or non-tar-
geting scrambled siRNA (On-Targetplus, Dharmacon) by 
Nucleofection (Amaxa). Due to high expression levels of 
HSP90 nucleofection was repeated after 48 h. Cells were 
harvested 48 h after second nucleofection. Tyrosine phos-
phorylation of STAT3, -5 and -6 as well as protein expression 
of HSP90 (rat-anti-HSP90 mAB, Stressgen), STAT3, -5, -6, 
Jak1, -2, -3, Tyk2 and Actin was analysed by immunoblot. (A) 
Downregulation of HSP90 by siRNA reduced tyrosine phos-
phorylation of STAT3, -5 and -6 in L428 cells. (B) Downregu-
lation of HSP90 by siRNA led to reduced protein expression 
of Jak1, -2, -3 and Tyk2 in L428 cells. (C) Reduced cell prolif-
eration was observed by downregulation of HSP90 in L428 
cells. cHL cell proliferation was measured by 3H-Thymidin 
incorporation after 48 h after second nucleofection. 3H-Thy-
midin was added 16 h – 18 h before harvesting. The data is 
depicted as percentages (Scrambled = 100%) and error bars 
mark the standard deviation of three replications.Publish with BioMed Central    and   every 
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